Dizal's ZEGFROVY® Emerging as a Leader in Advanced NSCLC Treatment Dizal's clinical findings for ZEGFROVY® reveal promising antitumor efficacy as a front-line therapy against advanced NSCLC with uncommon mutations.

Dizal's ZEGFROVY® Emerging as a Leader in Advanced NSCLC Treatment #China #Shanghai #NSCLC #Dizal #ZEGFROVY®

Dizal's Promising Phase 3 Study Results for ZEGFROVY in Lung Cancer Treatment Dizal has unveiled significant Phase 3 results for ZEGFROVY, showcasing enhanced survival rates in lung cancer patients with EGFR mutations.

Dizal's Promising Phase 3 Study Results for ZEGFROVY in Lung Cancer Treatment #Shanghai #NSCLC #Dizal #ZEGFROVY

Dizal Reveals Promising Hematology Pipeline Developments at ASH 2025 Dizal Pharmaceuticals showcased new advancements in its hematology pipeline, presenting promising data on golidocitinib and birelentinib during ASH 2025.

Dizal Reveals Promising Hematology Pipeline Developments at ASH 2025 #China #Shanghai #Dizal #Golidocitinib #SSE688192

China NMPA Conditionally Approves Golixitinib Capsules for Market

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#ChinaPharma #OncologyInnovation #Golixitinib #PTCL #Dizal #NMPA #DengYueMedicine #PharmaceuticalExports #JAKInhibitor #ChineseInnovativeDrugs

Dizal Unveils Groundbreaking Lung Cancer Treatments at 2025 WCLC Conference At the 2025 World Conference on Lung Cancer, Dizal presented innovations in treating non-small cell lung cancer, showcasing promising results with ZEGFROVY and golidocitinib.

Dizal Unveils Groundbreaking Lung Cancer Treatments at 2025 WCLC Conference #China #Shanghai #Dizal #Golidocitinib #ZEGFROVY

Dizal's Innovative Drug Birelentinib Earns Fast Track Status for CLL/SLL Treatment Dizal's birelentinib has received Fast Track Designation from the FDA for treating relapsed/refractory CLL/SLL, showing promising efficacy in clinical trials.

Dizal's Innovative Drug Birelentinib Earns Fast Track Status for CLL/SLL Treatment #Shanghai #United_States #CLL/SLL #Dizal #Birelentinib

FirstWord

#AbbVie #Biogen #BMS #CapstanTherapeutics #CARTtherapies #Gilead #JnJ #Novartis #ParvusTherapeutics #SAGETherapeutics #SupernusPharmaceuticals #UmojaBiopharma #4DMolecularTherapeutics #4DMT #Regeneron #Tecvayli #GSK #Dizal #UnicyciveTherapeutics #AstraZeneca
firstwordpharma.com/story/5978127

Dizal set to bring lung cancer drug Zegfrovy to US Dizal gets US approval for an oral therapy for EGFR exon 20-mutated NSCLC, offering some patients an alternative to J&J's intravenous Rybrevant

Miss it on the moment? Catch up with some of our news from yesterday: #Dizal gets US approval for an oral therapy for EGFR exon 20-mutated #NSCLC, offering some patients an alternative to J&J's intravenous Rybrevant.

pharmaphorum.com/news/dizal-s...

Dizal's ZEGFROVY® Emerges as the First Targeted Oral Treatment for NSCLC Dizal's ZEGFROVY® has achieved FDA accelerated approval, marking a breakthrough for treating lung cancer with specific mutations.

Dizal's ZEGFROVY® Emerges as the First Targeted Oral Treatment for NSCLC #Shanghai #United_States #Dizal #Lung_Cancer #ZEGFROVY

Dizal Achieves Major Milestone in NSCLC Treatment with Sunvozertinib Clinical Trial Enrollment Completion Dizal successfully completes enrollment for WU-KONG28 trial, evaluating sunvozertinib for NSCLC patients with specific genetic mutations, marking a significant step forward in cancer treatment.

Dizal Achieves Major Milestone in NSCLC Treatment with Sunvozertinib Clinical Trial Enrollment Completion #China #Shanghai #NSCLC #Dizal #Sunvozertinib

Dizal Unveils Groundbreaking Hematologic Cancer Therapies at EHA and ICML 2025 Dizal Pharmaceutical showcases two innovative treatments, golidocitinib and DZD8586, presenting their promising results in hematologic malignancies at major international conferences.

Dizal Unveils Groundbreaking Hematologic Cancer Therapies at EHA and ICML 2025 #None #DZD8586 #Dizal #Golidocitinib

Dizal to Showcase Drug Advances in Hematologic and Lung Cancers at ASCO 2025 Dizal Pharmaceutical plans to present outstanding results of its innovative therapies for hematological malignancies and lung cancer at ASCO 2025.

Dizal to Showcase Drug Advances in Hematologic and Lung Cancers at ASCO 2025 #China #Shanghai #DZD8586 #Dizal #DZD6008

Dizal Unveils Promising Clinical Results for Lymphoma Treatments at Upcoming Global Conferences Dizal will showcase recent clinical data on golidocitinib and DZD8586, targeting lymphoma treatments, at major international hematology conferences.

Dizal Unveils Promising Clinical Results for Lymphoma Treatments at Upcoming Global Conferences #China #Shanghai #DZD8586 #Dizal #Golidocitinib

Dizal to Present Innovative Data on Cancer Treatments at ASCO 2025 Dizal will reveal groundbreaking studies in hematologic cancers and lung cancer treatment at the ASCO 2025 conference, focusing on their innovative drugs DZD8586 and DZD6008.

Dizal to Present Innovative Data on Cancer Treatments at ASCO 2025 #China #Shanghai #DZD8586 #Dizal #DZD6008

Dizal's Golidocitinib Emerging as a Strong Contender for NSCLC Treatment Resistant to Immunotherapies Dizal's golidocitinib, a JAK1 inhibitor, shows promise in treating NSCLC patients resistant to anti-PD-1 therapies. Results expected at ELCC 2025.

Dizal's Golidocitinib Emerging as a Strong Contender for NSCLC Treatment Resistant to Immunotherapies #China #Shanghai #NSCLC #Dizal #Golidocitinib

Dizal's Sunvozertinib Receives FDA Priority Review as a New Treatment for NSCLC Dizal's new drug application for Sunvozertinib has received priority review by the FDA, marking a significant step for NSCLC treatment options.

Dizal's Sunvozertinib Receives FDA Priority Review as a New Treatment for NSCLC #Shanghai #USA #FDA #Dizal #Sunvozertinib

Dizal Unveils Promising Data for Sunvozertinib Against Resistant Lung Cancer Dizal shares positive pooled data on sunvozertinib, showcasing its effectiveness in treating non-small cell lung cancer resistant to EGFR inhibitors.

Dizal Unveils Promising Data for Sunvozertinib Against Resistant Lung Cancer #China #Shanghai #NSCLC #Dizal #Sunvozertinib

Dizal Unveils Promising DZD8586 Data at 2024 ASH Annual Meeting for B-cell Non-Hodgkin Lymphoma Dizal has presented new findings on DZD8586, a LYN/BTK dual inhibitor, showing its efficacy and safety for B-NHL at the recent ASH Meeting.

Dizal Unveils Promising DZD8586 Data at 2024 ASH Annual Meeting for B-cell Non-Hodgkin Lymphoma #China #Shanghai #DZD8586 #Dizal #B-cell_Lymphoma